Search results
Results From The WOW.Com Content Network
It is published by Elsevier and the editor-in-chief is Marianna Kruithof-de Julio (University of Bern) The Gene Family of journals comprises the journals Gene, Gene Reports, Human Gene, and Plant Gene. According to the Journal Citation Reports, the journal has a 2022 impact factor of 3.5. [1]
The Journal of Gene Medicine is a monthly peer-reviewed medical journal covering gene therapy and other uses of genetic technologies for medical purposes. It was established in 1999 and is published by John Wiley & Sons. The editors-in-chief is Gening Jiang (Tongji University).
Cambiogenplasmid (Neovasculgen): treatment for vascular endothelial growth factor peripheral artery disease Ciltacabtagene autoleucel (Carvykti): treatment for multiple myeloma [ 6 ] Delandistrogene moxeparvovec (Elevidys): treatment for Duchenne muscular dystrophy [ 7 ] [ 8 ]
2023 was a strong year for innovative new drugs, with new medications for Alzheimer’s disease, weight loss, and the first treatment based on the gene-editing technology CRISPR. But 2024 is also ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
About 5.3 million people on Medicare used the drugs between Nov. 1, 2023, and Oct. 1, 2024, according to the CMS. Together, the 15 drugs selected accounted for $41 billion, or 14%, of total ...
This page was last edited on 8 August 2024, at 14:03 (UTC). ... List of bioinformatics journals. 3 languages ...
The gene therapy will compete with Australia-based CSL Behring’s Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. That drug has a similar list price of $3.5 million ...